Akari Therapeutics (NASDAQ:AKTX) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of Akari Therapeutics (NASDAQ:AKTX) in a report published on Sunday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Akari Therapeutics Stock Up 2.2 %

NASDAQ:AKTX opened at $1.41 on Friday. The business’s 50 day moving average is $1.51 and its two-hundred day moving average is $2.65. Akari Therapeutics has a 52 week low of $0.90 and a 52 week high of $4.40.

About Akari Therapeutics

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.